Medical Journals

Effects of Rgh-237 [N-{4-[4-(3-aminocarbonyl-phenyl)-piperazin-1-yl]-butyl}-4-bromo-benzamide], an Orally Active, Selective Dopamine D(3) Receptor Partial Agonist in Animal Models of Cocaine Abuse.

Authors:
  • Gyertyán István
  • Kiss Béla
  • Gál Krisztina
  • Laszlovszky István
  • Horváth Attila
  • Gémesi Larisza I
  • Sághy Katalin
  • Pásztor Gabriella
  • Zájer Mária
  • Kapás Margit
  • Csongor Eva Agai
  • Domány György
  • Tihanyi Károly
  • Szombathelyi Zsolt

From: Department of Behavioral Pharmacology, Gedeon Richter Plc., P.O. Box 27, Budapest, Hungary. i.gyertyan@richter.hu

The Journal of pharmacology and experimental therapeutics

  • Publish Date: Mar 2007
  • ISSN: 0022-3565
  • Volume: 320
  • Issue: 3
  • Pages: 1268-78
  • Medium: Print
  • Language: English
  • Citation (JAMA): Gyertyán István, Kiss Béla, Gál Krisztina, et al. Effects of Rgh-237 [N-{4-[4-(3-aminocarbonyl-phenyl)-piperazin-1-yl]-butyl}-4-bromo-benzamide], an Orally Active, Selective Dopamine D(3) Receptor Partial Agonist in Animal Models of Cocaine Abuse.. J. Pharmacol. Exp. Ther. Mar 2007;320:1268-78

Abstract

Dopamine D(3) receptor partial agonism has been suggested as a potential therapeutic intervention in cocaine addiction. RGH-237 [N-{4-[4-(3-aminocarbonyl-phenyl)-piperazin-1-yl]-butyl}-4-bromo-benzamide] was identified as a novel selective dopamine D(3) receptor partial agonist and used for testing this hypothesis in animal models. The compound showed nanomolar affinity to human (K(i) = 6.7 nM) and rat (K(i) = 1.6 nM) D(3) receptors with an intrinsic activity of approximately 50%. It possessed several hundredfold selectivity over the D(2) receptor. The molecule bound with moderate (100-250 nM) affinity to 5-hydroxytryptamine 1A (5-HT(1A)) and nonselectively labeled opiate receptors. RGH-237 proved to be practically inactive on more than 40 other targets, including monoaminergic, cholinergic, GABAergic, and glutamatergic receptors. In rats orally administered RGH-237 was well and rapidly absorbed yielding 41% oral bioavailability. At its pharmacologically active dose (10 mg/kg p.o.), the brain concentration of RGH-237 reached 110 ng/g. Its blood and brain levels were sustained for 3 h. RGH-237 at the oral dose of 10 mg/kg moderately but significantly inhibited the acquisition of cocaine-induced place preference, although by itself, it had no place-conditioning effect. The compound did not affect fixed ratio 1 cocaine self-administration. In a reinstatement paradigm of cocaine self-administration, the compound potently and dose-dependently blocked the cue-induced cocaine-seeking behavior of rats at 10 and 30 mg/kg oral doses. RGH-237 did not affect seeking activity for natural rewards, such as sucrose and water. It did not exert notable effect on spontaneous motor activity of rats. Our results demonstrate that selective D(3) partial agonists may be an effective therapeutic means in the treatment of cocaine abuse.

Mesh Headings (Keywords): Administration, Oral, Animals, Benzamides, Binding, Competitive, Cocaine-Related Disorders, Conditioning (Psychology), Disease Models, Animal, Dose-Response Relationship, Drug, Male, Motor Activity, Piperazines, Rats, Rats, Wistar, Receptors, Dopamine D2, Receptors, Dopamine D3, Structure-Activity Relationship


Check for Full Text / PubMed Unique Identifier (PMID): 17170312


This abstract is part of PubMed, a service of the U.S. National Library of Medicine. PubMed includes more than 17 million citations from MEDLINE and other life science journals for biomedical articles. See Copyright and Disclaimers.

Linked medical terms appearing on this page are added by Healia to help readers find more information and are not part of the original PubMed document.

The data herein was last updated on July 8th, 2008 and may not reflect the most current and accurate data available from NLM.


Advertisements

About | Privacy Policy | Business Solutions | Advertise | Contact | Add Healia to your site

©2012. Healia / Meredith Corporation  

Use of this site constitutes acceptance of our Terms of Service and Privacy Policy. All content on this Web site, including medical opinion and any other health-related information, is for informational purposes only and should not be used for a specific diagnosis or individual treatment plan for any situation. Use of this site and the information contained herein does not create a doctor-patient relationship. Always seek the direct advice of your doctor in connection with any questions or issues you may have regarding your own health or the health of others.